Search results
Results from the WOW.Com Content Network
Amisulpride is approved and used at low doses in the treatment of dysthymia and major depressive disorder. [10] [20] [11] [21] [22] [23] Whereas typical doses used in schizophrenia block postsynaptic dopamine D 2-like receptors and reduce dopaminergic neurotransmission, low doses of amisulpride preferentially block presynaptic dopamine D 2 and D 3 autoreceptors and thereby disinhibit dopamine ...
Sanofi was founded in 15 February 1973 [5] as a subsidiary of Elf Aquitaine (a French oil company subsequently acquired by Total), when Elf Aquitaine took control of the Labaz group, a pharmaceutical company formed in 1947 by Sociéte Belge de l'Azote et des Produits Chimiques du Marly; [6] Labaz developed benziodarone in 1957.
Hyoscine butylbromide, also known as scopolamine butylbromide [4] and sold under the brandname Buscopan among others, [5] is an anticholinergic medication used to treat abdominal pain, esophageal spasms, bladder spasms, biliary colic, [6] and renal colic. [7] [8] It is also used to improve excessive respiratory secretions at the end of life. [9]
Leflunomide, sold under the brand name Arava among others, is an immunosuppressive disease-modifying antirheumatic drug , [8] used in active moderate-to-severe rheumatoid arthritis and psoriatic arthritis. It is a pyrimidine synthesis inhibitor that works by inhibiting dihydroorotate dehydrogenase. [9] Bottle of Leflunomide (Arava) and tablet
(Reuters) -Sanofi plans to seek U.S. approval for its best-selling anti-inflammatory drug Dupixent to be used in the treatment of "smoker's lung", also known as COPD, after a second large trial ...
Maalox was a brand of antacid owned by Sanofi. Their main product is a flavored liquid containing a suspension of aluminum hydroxide and magnesium hydroxide , which act to neutralize or reduce stomach acid , for the purpose of relieving the symptoms of indigestion , heartburn , gastroesophageal reflux disease , and also stomach or duodenal ulcers.
(Reuters) -Sanofi vaunted 12 drugs in development with the potential to make more than $1 billion in annual sales, but failed to reverse a recent plunge in its stock when it gave up a 2025 profit ...
Tablets – Orlept by Wockhardt and Epilim by Sanofi; Oral solution – Orlept Sugar Free by Wockhardt and Epilim by Sanofi; Syrup – Epilim by Sanofi-Aventis; Intravenous injection – Epilim Intravenous by Sanofi; Extended release tablets – Epilim Chrono by Sanofi is a combination of sodium valproate and valproic acid in a 2.3:1 ratio.